Molecular targeted therapies have shown considerable efficacy in treating metastatic renal cell carcinoma (mRCC).
However, many patients still experience tumor recurrence or metastasis due to drug resistance.
Despite extensive research on resistance mechanisms, there is a lack of comprehensive bibliometric studies examining the overall characteristics of targeted therapy resistance in renal cell carcinoma.
